

CALLISTO PHARMACEUTICALS INC

Form 8-K

December 21, 2006

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **December 19, 2006**

**Callisto Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of incorporation or organization)

**001-32325**

(Commission  
File Number)

**13-3894575**

(IRS Employer  
Identification No.)

**420 Lexington Avenue, Suite 1609**

**New York, New York 10170**

(Address of principal executive offices)

**Registrant's telephone number, including area code: (212) 297-0010**

(Former name or former address, if changed since last report)

## Edgar Filing: CALLISTO PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.02** **Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.**

On December 19, 2006, Donald Picker, Ph.D., Callisto Pharmaceuticals, Inc. (the Company) Executive Vice President, Research & Development resigned from his position with the Company.

**Item 8.01. Other Events.**

Attached as Exhibit 99.1 and incorporated herein by reference, is a press release announcing the filing of a lawsuit against Tapestry Pharmaceuticals, Inc., Leonard P. Shaykin and Kai P. Larson for breach of a confidential disclosure agreement between the Company and Tapestry.

**Item 9.01 Financial Statements and Exhibits**

(c) Exhibits.

99.1 Press Release of Callisto Pharmaceuticals, Inc. dated December 21, 2006.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: December 21, 2006

CALLISTO PHARMACEUTICALS, INC.

By: /s/ Gary S. Jacob  
Gary S. Jacob, Ph.D.  
Chief Executive Officer